Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce the assignment of billing code (0579U) by the American Medical Association (AMA) for the next-generation of the PromarkerD test system.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF) is pleased to announce a major $6 million expansion of the WA Proteomics Facility, in partnership with The University of Western Australia (UWA), the WA State Government and Bioplatforms Australia.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, is pleased to announce that the Japan Patent Office has granted the Company its first patent for PromarkerEndo, the proprietary diagnostic blood test for endometriosis.
Proteomics International Laboratories Ltd (ASX:PIQ) Next-gen PromarkerD test system released for predicting DKD
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics, proudly announces the initial US launch of its groundbreaking predictive test for diabetic kidney disease, PromarkerD, at the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago, Illinois.
Proteomics International Laboratories Ltd (ASX:PIQ) (OTCMKTS:PIQLF), a pioneer in precision diagnostics is pleased to announce the publication of clinical validation results in the journal Proteomes showing its PromarkerEso blood test can diagnose esophageal adenocarcinoma with high accuracy.
Proteomics International Laboratories Ltd (ASX:PIQ) has unveiled landmark clinical data confirming its Promarker(R)Endo blood test as a highly accurate, non-invasive diagnostic tool for endometriosis.
